Libtayo, chemo combo clears lung cancer trial two years early. But can it compete with Keytruda?
With the sixth checkpoint inhibitor on the US market, Regeneron and Sanofi sought to create their own market for Libtayo by going after indications other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
